Chemotherapy News and Research

Latest Chemotherapy News and Research

MUHC unveils new Lung Cancer Navigation Program

A diagnosis of lung cancer can come as a hard blow. The disease has one of the highest mortality rates of all cancers and the sheer complexity of therapy - often involving radiation, chemotherapy and surgery - can leave patients feeling confused and isolated. To help these patients navigate through the complicated treatment process and medical appointments, the MUHC has unveiled its new Lung Cancer Navigation Program (LCNP).

8 Jan 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

In a first-ever initiative, renowned health-care providers identify and describe how cancer treatment-related toxicities have a negative effect on quality of life from the perspective of patients and survivors.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

Eisai acquires AkaRx for approximately $255 million

Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company, AkaRx, Inc. (Headquarters: Bridgewater, New Jersey, CEO: Robert E. Desjardins), for approximately $255 million.

6 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

Article about Enox Biopharma's self-sterilizing technology for catheters accepted for publication

A prestigious peer-review journal will publish an article in its January 2010 edition outlining a Vancouver BC based biomedical technology company's solution to the growing problem of hospital patients acquiring bacterial infections. The article about Enox Biopharma's self-sterilizing technology for catheters (patent pending) was accepted for publication in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology and one of the most prominent publications in the field.

6 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

Preclinical data of Geron's telomerase inhibitor drug published

Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

6 Jan 2010

Findings reveals 'limpet-like' proteins can play a key role in DNA repair

UK scientists have found that a crafty family of 'limpet-like' proteins can play a crucial role in repairing DNA damage - according to two research papers published in Nature today (Wednesday). These findings could pave the way to the design of new anti-cancer drugs which target this process.

6 Jan 2010

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

BioVectra Inc. announced today it has signed agreements with Sandoz Inc. of Princeton, New Jersey, for Sandoz to commercialize and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere®, developed by BioVectra.

6 Jan 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

MUHC unveils new Lung Cancer Navigation Program

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Epigenetic diagnosis and therapies, a new strategy for treating cancer

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Eisai acquires AkaRx for approximately $255 million

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

Article about Enox Biopharma's self-sterilizing technology for catheters accepted for publication

New research may yield more effective treatment for childhood leukemia

Health Canada approves Zyclara Cream for multiple actinic keratoses

Preclinical data of Geron's telomerase inhibitor drug published

Findings reveals 'limpet-like' proteins can play a key role in DNA repair

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

Radiologists use new interventional NanoKnife technique to treat lung cancer

MindUp Cancer Project integrated into HIRU

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

FDA approves minimally invasive procedure for treating benign and malignant tumors

New campaign to provide retreats for women recovering from breast cancer launched

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in